ID: ALA5266701

Max Phase: Preclinical

Molecular Formula: C30H29BrN2O6S2

Molecular Weight: 657.61

Representations

Canonical SMILES:  O=C(OC[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccc(Br)cc1)[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccccc1

Standard InChI:  InChI=1S/C30H29BrN2O6S2/c31-25-16-18-28(19-17-25)40(35,36)32-26(20-23-10-4-1-5-11-23)22-39-30(34)29(21-24-12-6-2-7-13-24)33-41(37,38)27-14-8-3-9-15-27/h1-19,26,29,32-33H,20-22H2/t26-,29-/m1/s1

Standard InChI Key:  ULQDLVLVQKVZBG-GGXMVOPNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 657.61

Molecular Weight (Monoisotopic): 656.0650

AlogP: 4.47

#Rotatable Bonds: 13

Polar Surface Area: 118.64

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.49

CX Basic pKa:

CX LogP: 6.13

CX LogD: 6.12

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.21

Np Likeness Score: -0.56

References

1. Huang H, Zhang Y, Xu X, Liu Y, Zhao J, Ma L, Lei J, Ge W, Li N, Ma E, Li Y, Yuan L..  (2023)  Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer cells.,  80  [PMID:36427655] [10.1016/j.bmcl.2022.129087]

Source

Source(1):

• Scientific Literature